Annexon’s ANX007 Misses GA Endpoint, But May Have Visual Acuity Path Forward
Executive Summary
The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.
You may also be interested in...
Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence
Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry.
Apellis Set For Blockbuster Success With Syfovre, The First Approved Geographic Atrophy Drug
Around five million people worldwide suffer from geographic atrophy, and Apellis’s drug will be the first to offer hope of slowing the disease’s progress, as it reaches the US market at a price comparable to the VEGF inhibitors.
Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain
The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.